Slide BLUESKY IMMUNOTHERAPIES NEXT GENERATION IMMUNOTHERAPY AGAINST CANCER AND INFECTIOUS DISEASES

OUR MISSION


BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and antiviral properties. BlueSky uses these delNS- mediated properties for therapies against cancer and viral infectious diseases.

TECHNOLOGY


The high level of interferon induced by the delNS vector activates immunological defence reactions against cancer. It also stimulates the production of antiviral molecules:

Immunostimulation / Immunomodulation

– NK –

activates Natural Killer Cells

– CTL –

activates Cytotoxic T-Cells

– DC –

activates Dendritic Cells

– Treg –

inhibits Immunosuppressive Regulatory T-Cells

– ΜΦ –

activates Macrophage

Antiviral molecules / Inhibition of viral replication

– ISG15 –

Interferon stimulated gene 15

– OAS –

Oligoadenylate synthetase

– PKR –

Protein Kinase R

– Mx –

Interferon-induced GTP binding protein

Cancer treatment by delNS-based Immunotherapy

 

Eliminating tumours based on innovative delNS technology


Viennese biotech company BlueSky Immunotherapies uses its proprietary, innovative platform technologies in the fight against cancer and infectious diseases. Find out what important milestone for next-generation cancer therapy has been achieved.

 

REFERENCES / PUBLICATIONS delNS


The original paper Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems (Virology 252,324) has accumulated 1188 citations in peer – reviewed journals (Google Scholar, March 2021).

The immunogenic properties and safety of delNS-based viruses have been widely published in top journals. A selection of corresponding papers is provided below:

PIPELINE


CANCER

Preclinical studies have proven that the immunostimulatory properties of the delNS-vector “delNS/E6E7” destroy tumours. The vector’s potential for fighting metastases has also been demonstrated in animal models. Moreover, we have shown that delNS/E6E7 eliminates aggressive and incurable papilloma virus induced tumours in horses. Based on these promising results, BlueSky is currently conducting a phase I clinical trial with delNS/E6E7 for tumour elimination and prevention of cervical carcinoma in humans. Subsequently, its efficacy against cervical lesions, cervical cancer as well as head and neck cancer will be assessed in phase II trials.

APPLY FOR OUR HPV 16 STUDY IN VIENNA

INFECTIOUS DISEASES

Interferon also activates endogenous antiviral molecules such as the so-called protein kinase K (PKR). Based on this observation, we have developed Pekarin. As a first application, we have successfully tested Pekarin in animal models against influenza viruses. It was found that severity and duration of influenza were both significantly reduced. In principle, Pekarin can be used to fight all viruses, and, accordingly, the next indication to be tested is its efficacy against COVID-19.

OUR TEAM


Thomas Muster

– CEO –

muster-bw
Over 20 years biotech experience; more than 50 publications; 30 patents; has developed vaccines licensed to Baxter and Boehringer

● Vivaldi Biosciences
● AVIR Green Hills Biotechnology
● Mount Sinai School of Medicine

Michael Tscheppe

– CFO –

mtscheppe
Over 20 years in finance, business administration & marketing; university lecturer

● Nuvonis Technologies
● AVIR Green Hills Biotechnology
● University of Applied Sciences
● Post AG

Markus Wolschek

– CSO –

wolschek-bw
Lead scientist; virology, genetic-engineering and product development expert, more than 30 publications and several patents

● AVIR Green Hills Biotechnology
● Medical University Vienna


Manfred Reiter

– CTO –

reiter-bw
More than 20 years as Senior Vice President in the vaccine business; cell bank, process development and manufacturing expert

● Nuvonis Technologies
● Hookipa Biotech
● Baxter Bioscience
● Immuno AG

Joachim Seipelt

– COO –

seipelt-bw
PhD in Biochemistry, expert in biotech management and funding, industrial cooperation and licensing, university lecturer

● Nuvonis Technologies
● Austria Wirtschaftsservice
● AVIR Green Hills Biotechnology
● Max Perutz Labs Vienna
● Medical University Vienna

ADVISORY BOARD


Rüdiger Herrmann

– Squire Patton Boggs –

Noel Barrett

– CEO Affiris –

Josef Poandl

– Investor –

NEWS & EVENTS


Immunotherapy against cancer: phase 1 clinical trial interim analyses

BlueSky Immunotherapies reaches first milestone with its clinical testing using delNS/E6E7 for treating HPV-associated tumours: Treatment of first cohort is safe and tolerable. Next dose level approved.

BlueSky Immunotherapies at the BIO Digital

Bio-Europe Spring Digital is the largest springtime digital partnering event for the biotech industry, where thousands of global biotech leaders and innovators meet. Looking forward to connecting with new partners!

Patent protection for innovative technology-platform

BlueSky Immunotherapies has secured its patents that cover a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein.

FUNDING


CONTACT US


Thank you for visiting us. Please keep an eye on our site as we will add new content very soon. In the meantime, let’s stay in touch. If you have any question, query or idea, please send us an email.

    Message*


    We are looking forward to connecting with our business partners.
    BlueSky Immunotherapies